Skip Nav Destination
Research Watch| February 24 2023
Nivolumab Plus Relatlimab Is Safe and Efficacious in Pretreated Melanoma
Online Issn: 2159-8290
Print Issn: 2159-8274
©2023 American Association for Cancer Research
American Association for Cancer Research
Cancer Discov OF1.
Nivolumab Plus Relatlimab Is Safe and Efficacious in Pretreated Melanoma. Cancer Discov 2023; https://doi.org/10.1158/2159-8290.CD-RW2023-032
Download citation file:
Don't already have an account? Register
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your InstitutionSign in via your Institution